Dana-farber-cancer Institute Inc.

Genetics Institute, Inc.

Other

Dana Farber Cancer Inst.

Charles D Stiles

Barrett J Rollins

Gordon G Wong

Pamela Ann Silver

Prescott Deininger

Mark K Mercola

Tom Roberts

Richard J Epstein

A novel human cytokine, JE factor, and processes for producing it are disclosed. JE may be used in pharmaceutical preparations for stimulating and/or enhancing immune responsiveness and in wound healing and related tissue repair. containing the factor.

DNA encoding human JE cytokine

A method of suppressing tumor formation in a vertebrate by administering JE/MCP-1 is described. Also described are methods of treating localized complications of malignancies and methods of combatting parasitic infection by administering JE/MCP-1.

Suppressing tumor formation using cells expressing JE/monocyte chemoattractant protein-1

The invention features two methods for making eucaryotic trans-dominant suppressor genes encoding polypeptide translation products capable of suppressing the activity of a growth factor that requires an oligomeric state for function, suppressor genes made by the methods, protein products of the suppressor genes, and methods for using these genes and protein products.

Trans-dominant suppressor genes for oligomeric proteins

A chimeric protein having an (a) IRE1 or analog cytoplasmic kinase domain, (b) a transmembrane domain, and (c) a ligand binding domain of a transmembrane protein other than IRE1 is described. This protein can be used to identify and/or screen for ligands and other molecules that interact with the ligand binding domain.

Genetic selection method for identifying ligands for transmembrane proteins

Activation-state-specific and protein-specific antiphosphoprotein antibodies and methods for their production are disclosed. Also disclosed are methods for evaluating the prognosis and therapeutic outcome for patients using the antiphosphoprotein antibodies and methods for characterizing the activation state of a reversibly phosphorylated protein, kits including the antibodies for use in characterizing the activation state of a protein, and methods for evaluating the agonist or antagonist activity of pharmaceutically useful compounds towards the conversion of a specific protein from its inactive to its active state.

Activation-state-specific phosphoprotein immunodetection

Human cytokine

A novel human cytokine, JE factor, and processes for producing it are disclosed. JE may be used in pharmaceutical preparations for stimulating and/or enhancing immune responsiveness and in wound healing and related tissue repair.

Growing community of inventors

Newton Centre, MA, United States of America

Charles D Stiles